
JP Power shares surge 14% after AGM lifts inverter sentiment
Jaiprakash Power Ventures Ltd
(JP Power) surged nearly 14% on Monday to close at Rs 21.57, gaining momentum after the company successfully concluded its 30th Annual General Meeting (
AGM
) over the weekend.
The AGM, held virtually on July 5, 2025, was conducted via video conferencing (VC)/other audio-visual means (OAVM), in line with the latest regulatory guidelines issued by the Ministry of Corporate Affairs (MCA) and SEBI.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Cardiólogo: El mejor método para un vientre plano después de los 50 (¡Es genial!)
Té mágico desintoxicante
Undo
During the meeting, all key resolutions outlined in the notice dated May 1, 2025, were presented, including adoption of financial statements, reappointment of directors, and approvals for auditor appointments and director remuneration. The company also enabled electronic voting through
CDSL
's e-voting platform, both before and during the AGM, ensuring transparency and shareholder participation.
JP Power Chairman Manoj Gaur addressed shareholders during the AGM, sharing key insights into the company's performance and outlook. The meeting was attended by 107 shareholders via video conferencing, including senior board members and committee heads.
The market responded positively to the company's governance and communication efforts, with increased investor confidence reflected in the day's sharp stock price movement.
Live Events
On the technical front, Jaiprakash Power Ventures Ltd. is showing strong
bullish momentum
:
The Relative Strength Index (RSI-14) stands at 69.5, indicating the stock is approaching overbought territory. For context, an RSI below 30 typically signals an oversold condition, while an RSI above 70 suggests the stock may be overbought and could be due for a pullback.
Additionally, the stock is trading above all 8 key Simple Moving Averages (SMAs) — ranging from the short-term 5-day to the long-term 200-day SMA. This alignment across timeframes is considered a bullish signal, reflecting sustained upward momentum and strong underlying trend strength.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
15 minutes ago
- Business Standard
RVNL bags LoA for OHE upgradation project from
Rail Vikas Nigam (RVNL) has been awarded a letter of acceptance (LoA) by the South Central Railway for a significant project valued at Rs 213.22 crore. The contract encompasses the design, supply, erection, testing, and commissioning of an overhead equipment (OHE) upgradation project. This involves converting the existing 1x25kV system to a 2x25kV feeding system, including associated feeder and earthing works. The scope of work covers the Duvvada-Rajahmundry and Samalkot-Kakinada Port sections of the Vijayawada Division, falling under South Central Railway. The total length of the project spans 195.5 track kilometers (RKM) / 391 equivalent track kilometers (TKM). The domestic contract has to be executed within a period of 24 months. Rail Vikas Nigam is in the business of executing all types of railway projects, including new lines, doubling, gauge conversion, railway electrification, metro projects, workshops, major bridges, construction of cable-stayed bridges, institution buildings, etc. The company reported a 4.05% decrease in consolidated net profit to Rs 459.15 crore in Q4 FY25 as against Rs 478.56 crore posted in Q4 FY24. Revenue from operations slipped 4.27% YoY to Rs 6,426.88 crore in the quarter ended 31 March 2025. The scrip shed 0.81% to end at Rs 381.55 on the BSE on Friday.


Business Standard
15 minutes ago
- Business Standard
NCC secures Rs 2,269-cr order from MMRDA for Mumbai Metro Line 6 project
NCC announced that it has received a Letter of Acceptance (LoA) worth Rs 2,269 crore from the Mumbai Metropolitan Region Development Authority (MMRDA) for work on the Mumbai Metro Line 6 project. The contract for Package 1-CA-232 of the Mumbai Metro Rail Project's Line 6 (Swami Samarth Nagar to Vikhroli EEH) encompasses the entire lifecycle of essential systems. This includes the design, manufacture, supply, installation, integration, testing, and commissioning of rolling stock, communication-based signaling & train control, telecommunication systems, platform screen doors, and depot machinery & plant. The execution timeline includes a 24-month construction period, followed by a 2-year Defect Liability Maintenance Period (DLMP), and an additional 5 years of comprehensive maintenance post-DLMP. NCC clarified that the transaction is not a related party transaction, and no promoters, promoter group entities, or group companies have any financial or other interest in the awarding authority. NCC is engaged in the infrastructure sector, primarily in the construction of industrial and commercial buildings, housing projects, roads, bridges, flyovers, water supply and environment projects, mining, power transmission lines, irrigation and hydrothermal power projects, etc. NCC reported a consolidated net profit of Rs 253.82 crore in Q4 FY25, up 6.12% as against Rs 239.16 crore posted in Q4 FY24. However, revenue from operations tumbled 5.45% to Rs 6,130.88 crore in Q4 FY25 as against Rs 6,484.88 crore posted in Q4 FY24. The scrip shed 0.78% to settle at Rs 221.75 on Friday, 12 July 2025.


Business Standard
15 minutes ago
- Business Standard
Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. Pashamylaram is a village located in Patancheru mandal of Medak district in Telangana, India. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. This GMP certificate is crucial for Gland Pharma as it pertains to marketing authorizations that list manufacturers located outside of the European Economic Area (EEA), allowing their products to be marketed within Denmark and potentially other EEA countries. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip had gained 0.89% to end at Rs 1859.05 on the BSE on Friday.